A meta-analysis of front-line therapy of osimertinib in treating non-small cell lung cancer

Our meta-analysis was designed to explored the efficacy and safety of osimertinib as front-line strategy in advanced non-small-cell lung cancer (NSCLC) whose tumors had sensitive EGFR mutations. Computerized search for trials from CENTRAL, PubMed, Cochrane EMBASE up May, 2021. The investigated include untreated NSCLC patients with EGFR-mutation. summarized outcomes 4 studies. Outcomes this study revealed that PFS significantly longer treated than standard EGFR-TKIs/placebo group. In terms subgroup analyses, better were found be higher Osimertinib, regardless sex, EGFR-mutated status, smoking history. Besides, improved CNS treatment-related AE no difference identified when comparing Osimertinib vs. comparable group (p > 0.05). results suggested First-line treatment achieved a clinically meaningful benefit tolerable AEs prior EGFR-TKI/placebo. Meanwhile, seemed option metastases. tolerability, more appropriate upfront therapy among EGFR-mutant NSCLC.